Best of Boston

What a coming-out party this past year has been for Moderna. For years the Cambridge company had been all-in on messenger RNA vaccines, the radical approach to disease prevention that attracted billions of dollars from investors but had yet to be proven in the real world. After its wildly successful vaccine put the startup on par with major drug manufacturers like Pfizer — not to mention helped break COVID-19’s grip on humanity — it’s clear that the bet has paid off.